2022 In-Person 3D Cell Culture Summit

2022 In-person 3D Cell Culture Summit

2022 In-person 3D Cell Culture Summit

September 21 and 22 | NYC

In the past several years, 3D cell culture has seen growing interest and acceptance across many critical research areas. With this adoption and implementation of new, sophisticated 3D models, has come the need to share knowledge on how to get started in and the best ways to optimize 3D cultures.

At the 2022 3D Cell Culture Summit in New York City, Corning brought together industry leaders and innovators from top academic and pharmaceutical organizations to:


  • Share ideas and information on current and future 3D applications, including spheroid, organoid and tissue models.
  • Review and discuss 3D applications, including practical information and tips for working with novel and advanced models.
  • Introduce new users to best practices and tips to get started in 3D cell culture.
  • Foster discussion and networking among industry leaders on 3D workflow optimization, trends, and innovation.

If you were unable to attend live, content is now available to view on demand.

Featured Speakers and Panelists

Robert Vries

Robert Vries, Ph.D.

CEO, HUB Organoids

 

Patient-derived Organoids – A Revolutionary New Model to Advance Precision Medicine

 

The initial discovery of adult stem cells in human epithelia such as the intestine and liver coupled with technology advancements in 3D culture have enabled the virtually unlimited, genetically, and phenotypically stable expansion of patient-derived organoids – or HUB Organoids® - from both normal and diseased tissue.

 

Over time, organoids have been shown to be a very powerful tool to study the biology of cancer, genetic diseases such as cystic fibrosis, and inflammatory conditions such as IBD or COPD. More recently, the predictive power of HUB Organoids was demonstrated in high profile publications that show high correlation of in vitro response with clinical outcome and the feasibility of accelerating a candidate compound to clinical trials in 5 years. HUB has pioneered organoid model development and the optimization of in vitro assays that can be applied to investigate disease biology and performing drug screenings. In his presentation Dr. Rob Vries, HUB CEO, will discuss the application of HUB Organoids to precision medicine approaches and how this can benefits patients across various diseases.

Amanda Linkous

Amanda Linkous, Ph.D.

Scientific Center Manager, NCI Center for Cancer Systems Biology of Small Cell Lung Cancer, Vanderbilt University

 

Organoids as a Model of Small Cell Lung Cancer Brain Metastasis

 

Small cell lung cancer (SCLC) is a highly aggressive, neuroendocrine tumor that accounts for approximately 15% of all lung cancer cases. Known for its ability to disseminate early, with a strong propensity to metastasize to the brain, SCLC is a recalcitrant cancer with very poor survival (5-year survival is less than 5%). Using a systems biology approach, we have developed 3D organoid models to capture the cell-cell interactions that underlie SCLC brain metastases.

Kacey Ronaldson-Bouchard, Ph.D.

Kacey Ronaldson-Bouchard, Ph.D.

Associate Research Scientist, Laboratory for Stem Cell and Tissue Engineering at Columbia University

 

Multi-organ Platform with Tissue-specific Niches Linked by Vascular Perfusion

 

We report the development of a model of human physiology in form of a multi-organ chip consisting of engineered human tissues linked by vascular flow with systemic interorgan communication for patient-specific drug screening and modeling of disease.

Nino Faleo

Nino Faleo, Ph.D.

Senior Scientist, Ambys Medicines

 

Enhancing Hepatocyte Function for Transplantation

 

Hepatocyte transplantation is a promising alternative therapy for many liver diseases, however, widespread adoption remains limited. In this study, we explored a multipronged approach to test the effect of 3D spheroids on graft function.

Bram Herpers, Ph.D.

Bram Herpers, Ph.D.

Executive Director, General Manager, CBNL

 

Image-based Organoid Screening Identifies a Therapeutic EGFR x LGR5 Bispecific Antibody

 

Patient-derived organoids (PDOs) are established by stimulating the maintenance and proliferation of (cancer) stem cells with WNT pathway activators and receptor tyrosine kinase (RTK) agonists in an extracellular matrix environment. Here we describe a large-scale image-based screen with dual-targeting (RTKxWNT) bispecific antibodies in a diverse panel or (metastatic) colorectal cancer organoids and (matched) normal organoid models. Out of more than 500 antibodies a potent EGFRxLGR5 bispecific antibody, MCLA-158, was identified. The antibody inhibited the outgrowth of a large number of different CRC PDO models, including KRAS mutant models, but shows minimal toxicity towards healthy colon organoids. Functionally, the antibody blocks RTK signaling by triggering EGFR degradation in an LGR5-dependent manner and was shown to block metastasis initiation and to be able to suppress the outgrowth of in vivo tumor models of several other cancer types. This study highlights Crown Bioscience’s application of organoids throughout the drug discovery process –from high throughput screening to patient stratification and mechanism of action studies.

Hilary Sherman

Hilary Sherman

Senior Scientist, Corning Life Sciences

 

CLS Practicum: Cell Based Applications using the Corning® Matribot® Bioprinter

This session will give a high-level overview of the Corning Matribot Bioprinter and how it can be used in various cell-based Applications. Much of the talk will focus on a recent application to dispense pancreatic cancer organoids accurately and consistently for drug testing. Dispensed organoid cultures were assessed for toxicity to several chemotherapeutics that are traditionally used for treating pancreatic cancer. This data demonstrates an automated way to screen for the best drug choice for an individual’s pancreatic cancer.

Ben Hopkins

Benjamin D. Hopkins, Ph.D.

Assistant Professor, Department of Genetics and Genomic Sciences, Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

 

Rapid Assessment of Patient Drug Sensitivity (RAPiDS) using 3D patient derived organoids

 

Precision Oncology has the potential to optimize treatment for individual patients. By integrating basic and clinical research pipelines, we seek to refine the selection of therapy for individual patients and functionally identify effective therapies.

Dennis Plenker, Ph.D.

Dennis Plenker, Ph.D.

Senior Staff Scientist, Xilis Inc.

 

High-throughput Single Agent and Combination Drug Screens Reveal Patient-specific Organoid Drug Responses in Pancreatic Cancer

 

Patient-derived models are the key of my research interests as their use is to my opinion key to finding more efficient treatments for cancer patients. For this approach I use Corning Matrigel® matrix to resemble the tumors matrix where it robustly propagates.

Amy Kauffman

Amy Kauffman, Ph.D.

Sr. Development Engineer, Corning Life Sciences

 

CLS Practicum: Advanced Spheroid Culture and Bioproduction of Extracellular Vesicles with the Corning® Elplasia® Flask

3D cell culture models, such as spheroids, have been proven to better mimic the in vivo environment compared to traditional monolayer culture models. The functional physiology in which cells organize themselves into 3D structures aid in the recapitulation of the cells’ behavior in their native environment. Spheroids in particular are becoming critical models for cancer research and advance therapy development, however, scaling to produce large quantities of high quality spheroids with current technologies and practice can be inefficient. At Corning, we have provided a solution, the Corning® Elplasia® Flask which enables the growth of thousands of spheroids of consistent size and geometry in the footprint similar to a T-75 flask. The Elplasia Flask is compatible with many cell types, including cancer, stem, and epithelial (normal), and can support viable spheroids up to 30 days. Further, this platforms offers a unique and easy-to-use 3D cell culture tool for biomolecule production, such as extracellular vesicles, that are easy to harvest via single media reservoir. The Corning® Elplasia flask supports 3D cell culture model breakthroughs that 2D cell culture simply cannot.

Enrique Podaza

Enrique Podaza, Ph.D.

Postdoctoral Associate in Physiology and Biophysics, Englander Institute for Precision Medicine, Weill Cornell Medicine

 

Next Generation Patient Derived Tumor Organoids

 

Patient-derived tumor organoids (PDTOs) have emerged as exceptional pre-clinical models as they preserved, in most of the cases, the mutational landscape and tumor-clonal heterogeneity of the primary tumors. Despite being extensively used in disease modelling as well as in precision medicine for drug testing and discovery, they still have some limitations. The main limitation is that during their establishment they lose all components of the tumor microenvironment (TME) which are known modulators of tumor response to therapeutic treatment as well as disease progression. Currently we are developing different co-culture strategies to reconstitute T-cells, Tumor associated macrophages and Cancer Associated Fibroblast to improve PDTOs value as pre-clinical models leading to the development of next generation PDTOs.

Francesco Cambuli

Francesco Cambuli, Ph.D.

Senior Scientist, Molecular Pharmacology Program, The Karuna Ganesh Laboratory, Sloan Kettering Institute

 

Modeling Colorectal Cancer Heterogeneity with Patient-derived Organoids
 

Tridimensional organoids increasingly enable the expansion of patient-derived cells in culture, but to what extent such models capture the cell state heterogeneity found in tumors remains an open question. Here, we describe our efforts toward improving the understanding and modeling of colorectal cancer cell heterogeneity.

Paul Romesser

Paul Romesser, M.D.

Director of Colorectal Anal Cancer

Department of Radiation Oncology 

Assistant Attending, Memorial Hospital

Assistant Member, Memorial Sloan Kettering Cancer Center

 

Translational Organoid Platform to Assess Radiation Sensitizers in Rectal Cancer


Abstract details coming soon. 

Won Hyuk Suh

Won Hyuk Suh, Ph.D.

Assistant Professor of Biotechnology, Department of Life Sciences, University of New Hampshire

 

Culturing Fibroblast and Neural Stem Cells on Crosslinked Bioprinted Methacrylated Gelatin

 

Abstract details coming soon

Elizabeth Abraham

Elizabeth Abraham, Ph.D.

Market Manager, 3D Cell Culture, Corning Life Sciences

 

What’s New and Next in 3D Cell Culture

 

Abstract details coming soon

Catherine Sheely Siler

Catherine (Sheely) Siler, Ph.D.

Field Application Scientist, Corning Life Sciences

 

3D Assay Optimization


Abstract details coming soon

Check back for updates!

Agenda